Yawen Wu Xiaoyan Zhang Lian Li Wen Yang Zhifeng Yan Chenglei Gu Zhe Zhang Jiahuan Zhou Lulu Liu Mingxia Ye Yuanguang Meng
10.2147/OTT.S375643
Onco Targets Ther
2022 Sep 12;15:973-979.
parp inhibitors antiangiogenic agents immunotherapy platinum resistance recurrent ovarian cancer
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/36118677/
Case Reports
PMC9480580
36118677
Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer
2022